Deepika Dhawan
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
151
Citations
2,042
Est. group size
~15
Recurring co-author estimate
Active years
31
Publishing since 1996
This researcher studies naturally occurring cancers in dogs, especially bladder (urothelial) cancer and brain tumors, as models for understanding and treating similar cancers in humans. Their work spans genetics of cancer risk in specific dog breeds, drug resistance mechanisms (including immune-checkpoint therapy resistance), and clinical trials of targeted cancer drugs like vemurafenib in canine patients. The research combines molecular biology techniques (proteomics, gene expression profiling) with veterinary clinical studies to advance comparative oncology.
Publication output has grown markedly over the past decade, with a large spike in 2023 and continued strong activity into 2025-2026, following a period of steadier, lower output in earlier years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Nanoparticulate Immunoactive Complex for Local Chemoimmunotherapy: From Murine Models to Pilot Canine Study
Cancer Research Communications · 2026
- Nanoparticulate Immunoactive Complex (IMAX) for local chemoimmunotherapy: From murine models to pilot canine study.
Open Access CRIS of the University of Bern · 2026
- Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAF <sup>V595E</sup> Mutation
Journal of Proteome Research · 2026
- Characterisation of Gene Expression in Canine Invasive Urothelial Carcinoma Using a <scp>NanoString</scp>‐Based Urine Assay
Veterinary and Comparative Oncology · 2025
- Abstract 4857: The role of tumor microenvironment lactic acid in the cancer cell resistance to anti-PD-L1 and anti-PD-1 blockade therapy
Cancer Research · 2025
- Hypoxia-inducible factor 1α expression does not differ between canine urothelial carcinoma and normal urinary bladder tissue
American Journal of Veterinary Research · 2025
- Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor
Molecular Therapy · 2024
- Evaluating Psychosocial Benefits of a Virtual Traumatic Brain Injury Support Group (P2-14.019)
Neurology · 2024
- Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1
npj Precision Oncology · 2024
- Abstract 3480: Alterations in the tumor microenvironment and key signaling pathways in naturally-occurring canine gliomas mirror those seen in human patients
Cancer Research · 2024
- Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study
The Veterinary Journal · 2023
- Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy‐treated diffuse large B‐cell lymphoma
Veterinary and Comparative Oncology · 2023
- PERSISTENT BLOODY DIARRHEA IN A HEART TRANSPLANT PATIENT
Journal of the American College of Cardiology · 2023
- Figure S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
2023
- Data from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
2023
- Figshare×8
- Cancer Research×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Bladder Cancer×4
- Frontiers in Oncology×3
- Rodrigo Mohallem
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Ketaki Bhide
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Deborah W. Knapp
Medicine · Purdue University West Lafayette
- Uma K. Aryal
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Lindsey M. Fourez
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile